Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Annals of the rheumatic diseases[TA])
13,900 results
  • Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. [Journal Article]
  • ARAnn Rheum Dis 2016 Nov 29
  • van Daalen EE, Rizzo R, … Rahmattulla C
  • CONCLUSIONS: The malignancy risk in patients with AAV was lower in rituximab-treated patients than in cyclophosphamide-treated patients. Notably, rituximab treatment was not associated with an increased malignancy risk compared with the general population. Rituximab could therefore be a safe alternative to cyclophosphamide in the treatment of AAV.
  • Infections and the risk of incident giant cell arteritis: a population-based, case-control study. [Journal Article]
  • ARAnn Rheum Dis 2016 Nov 28
  • Rhee RL, Grayson PC, … Tomasson G
  • CONCLUSIONS: Antecedent infections and, to a lesser extent, herpes zoster infections are modestly associated with incident GCA. These data provide population-level support for the hypothesis that long-standing alterations of the immune system are associated with susceptibility to GCA and suggest that herpes zoster is unlikely to play a major causal role in the pathogenesis of GCA.
New Search Next